Scope and US Patent Landscape for Drug Patent No. 10,278,935 (Ethyl Icosapentate 4 g/day Methods on Statin Therapy With Elevated Triglycerides)
US Patent 10,278,935 claims method-of-treatment IP focused on reducing coronary revascularization and/or unstable angina with about 4 g/day ethyl icosapentate (high omega-3 purity) in statin-treated subjects with fasting baseline triglycerides ~135 to 500 mg/dL, including specific inclusion/exclusion lipid targets, duration, and background therapy constraints. The claim set is structured to cover (i) primary prevention/at-risk cohorts and (ii) established CVD cohorts, with revascularization endpoints and additional cardiovascular risk reductions (MI, stroke, CV death).
Below is a structured analysis of the claim scope, claim-to-claim dependency, practical design-around pathways, and the likely patent estate and freedom-to-operate (FTO) pressure points relevant to US enforcement, generic/brand competition, and payer life-cycle strategy.
What does US Patent 10,278,935 claim: reducing coronary revascularization or unstable angina with ethyl icosapentate on statins?
Core independent claim architecture (Claim 1; Claim 19).
Independent Claim 1 (statin therapy; elevated triglycerides)
Claim 1 covers a method comprising:
- Background therapy: subject is on statin therapy
- Intervention: administer a pharmaceutical composition comprising about 4 g/day ethyl icosapentate
- Treatment duration: at least about 2 years
- Patient phenotype: fasting baseline triglyceride ~135 mg/dL to ~500 mg/dL
- Outcome: reducing risk of coronary revascularization and/or unstable angina
Independent Claim 19 (established cardiovascular disease; shorter baseline duration threshold)
Claim 19 is parallel but narrower in clinical characterization and duration:
- Established CVD determined by presence of any of:
- documented coronary artery disease
- documented cerebrovascular disease
- documented carotid disease
- documented peripheral arterial disease
- Intervention: about 4 g/day ethyl icosapentate
- Duration: at least about 4 months (note: far lower than Claim 1)
- Patient phenotype: fasting triglycerides ~135 to ~500 mg/dL
- Outcome: reducing risk of coronary revascularization and/or unstable angina
Key business implication: Claim 19 is a lower-duration carve-in for established CVD, which can compress time-to-infringement for early labeling expansions and post-approval studies that show endpoint effects over shorter windows.
How broad are the dosage and composition limits (4 g/day ethyl icosapentate; omega-3 purity ≥96 wt%)?
Dosage unit flexibility (Claims 2 and 21)
- Administered in 1 to 4 dosage units per day
This is a formulation-administration elasticity clause, designed to avoid non-infringement arguments based on whether the 4 g/day is split into 1, 2, 3, or 4 daily dosings.
Omega-3 purity (Claims 3 and 22)
- Ethyl icosapentate comprises at least about 96 wt.% of all omega-3 fatty acids in the composition.
Design-around pressure: a lower-purity omega-3 mix can fall outside this threshold, but that generally forces a shift to alternative products (or co-omega-3 strategies) rather than dose-titration or minor reformulation.
What patient selection criteria do the claims impose (fasting triglycerides; lipid profile bands; statin background; omega-3/niacin/fibrate washout)?
Primary phenotype: fasting triglycerides
Both independent claims use:
- fasting baseline triglycerides: ~135 to ~500 mg/dL
This is the primary inclusion window. Narrower triglyceride labels can reduce infringement risk, but the claim language is already broad within the stated range.
Lipid profile banding (Claims 5-6 and 24-25)
Dependent clauses specify one or more lipid metrics, each with bands:
- non-HDL-C ~200 to ~300 mg/dL
- total cholesterol ~250 to ~300 mg/dL
- VLDL-C ~140 to ~200 mg/dL
- HDL-C ~10 to ~30 mg/dL
- LDL-C ~40 to ~100 mg/dL
Scope effect: Because the claims say “one or more of” these metrics, the infringement trigger does not require all bands simultaneously. In practice, this increases likelihood of meeting the dependent limitations in real-world cohorts.
Measuring baseline lipid profile (Claims 4 and 23)
- requires a step of measuring baseline lipid profile prior to administering.
This is a common litigation hook because it can be met procedurally even if the drug itself is unchanged. It also aligns with clinical trial workflows and label-adjacent physician practice.
Exclusion / washout constraints (Claims 8-10 and 9-10 timeline ending at ≥6 months or up to multiple years)
Claim 8 adds a structured pre-treatment exclusion:
- not administered ≥200 mg/day niacin and/or fibrates for at least 28 days prior; and/or
- not administered omega-3 fatty acid prescription beginning 28 days prior; and/or
- not ingested dietary supplements comprising omega-3 fatty acids beginning 28 days prior
Claims 9-10 then address when the “no omega-3 exposure” period ends:
- ends no earlier than about 6 months after first administration
- can be about 6 months to 5+ years after first administration (depending on sub-variation in Claim 10)
Scope effect: These clauses can be used to defend against broad “standard-of-care” infringement by arguing real-world patients may not meet washout rules. Conversely, they give the patentee arguments to enforce in trial-like populations and structured clinical workflows.
How do the claims address endpoints: coronary revascularization, unstable angina, MI, stroke, cardiovascular death?
Revascularization and unstable angina
Both independent claims focus on:
- coronary revascularization and/or unstable angina
Dependent Claim 14 clarifies revascularization type:
- selected from elective and emergent coronary revascularization
Additional risk reductions (Claims 15-18; 27-30)
For Claim 1 line:
- Claim 15: reduces myocardial infarction
- Claim 16: reduces stroke
- Claim 17: reduces MI or stroke
- Claim 18: reduces cardiovascular death (via Claim 17 dependency)
For Claim 19 line:
- Claim 27: reduces MI
- Claim 28: reduces stroke
- Claim 29: reduces MI and stroke
- Claim 30: reduces cardiovascular death (via Claim 29 dependency)
Scope effect: The estate likely anticipates that infringement can be established via multiple endpoint label theories, which matters for enforcement strategy and for settlement leverage tied to clinical evidence generation.
What does “statin therapy” cover (Claim 7; ezetimibe optional)?
Claim 7 specifies:
- statin therapy comprises administering a statin and optionally ezetimibe.
Scope effect: This prevents easy workarounds arguing patients are “not on statins” if they also receive lipid-modifying adjuncts. Optional ezetimibe broadens compatibility with combination lipid management in practice.
How long does protection run based on the claimed treatment durations (2 years vs 4 months vs multiple years washout)?
Treatment duration limitations are not legal expiration terms, but they affect what clinical evidence is used to prove infringement.
Duration triggers
- Claim 1: ≥2 years ethyl icosapentate at ~4 g/day
- Claim 19: ≥4 months ethyl icosapentate at ~4 g/day
Duration in washout period (Claims 9-10)
- the “no omega-3 exposure” ending can be as long as 6 months, 1, 2, 3, 4, 5, or more than 5 years after first administration.
Practical impact: The shorter “≥4 months” in Claim 19 can increase infringement exposure in faster clinical programs, while longer washout variants can be leveraged to match trial designs and specific inclusion criteria.
Where do infringement and FTO risk concentrate in US practice?
1) Dose and composition lock
The claims anchor on:
- ~4 g/day ethyl icosapentate
- omega-3 purity ≥96 wt.%
These are the most difficult elements to design around without switching products or dose.
2) Patient lipid phenotype
Fasting triglycerides 135 to 500 mg/dL is broad. A company trying to reduce risk would need to avoid treating patients falling into that range. That is label and clinical-algorithm disruptive.
3) Background therapy alignment
Statin therapy is included; ezetimibe optional. This matches common CV prevention practice.
4) Endpoint framing
The independent claims are endpoint-driven. Even if a competitor’s label focuses on triglyceride lowering, enforcement can pivot to clinical endpoints if their study design or promotional claims align with the claimed outcomes.
What is the likely competitive and licensing pressure from adjacent icosapent ethyl IP families?
US Patent 10,278,935 is a method-of-use layer. For ethyl icosapentate, the broader commercial reality is that multiple IP generations usually exist:
- drug substance and composition claims on the ethyl ester,
- formulation and capsule composition claims,
- manufacturing/process claims,
- dose regimen claims,
- method-of-use claims across subpopulations and endpoints.
Method-of-use claims like 10,278,935 typically survive even when the active pharmaceutical ingredient is “generically available,” because generic manufacturing may not infringe unless they sell for the claimed method (often tied to label, instructions, physician inducement, or Hatch-Waxman Paragraph IV theories focused on approved indications).
Commercial consequence: a competitor may be able to market a product at a composition level but still face indication-specific constraints, promotional restrictions, or litigation centered on physician-directed use.
Which companies are likely impacted in the US market for ethyl icosapentate?
This analysis cannot name specific defendants or Paragraph IV challengers without the patent’s assignee/inventor and the litigation docket tied to 10,278,935. The claim scope alone indicates that any company seeking label positioning for:
- high-dose ethyl icosapentate (~4 g/day),
- in statin-treated patients,
- with fasting triglycerides ~135-500 mg/dL,
- targeting coronary revascularization/unstable angina endpoints,
would intersect this estate.
How strong is the patent estate around this claim theme (what makes method claims enforceable)?
Claim drafting signals strong enforceability
- Outcome-driven language (revascularization/unstable angina, MI, stroke, CV death)
- Patient selection by measurable lab parameter (fasting triglycerides; lipid bands)
- Duration and dosing regimen requirements
- Procedural step requiring measurement of baseline lipids
- Explicit compatibility with statin therapy and common lipid adjuncts
These features generally improve the patentee’s ability to map clinical practice or trial criteria to the claim elements.
Key weak-point candidates
Potential defenses in method-of-use infringement cases often involve:
- non-matching patient populations (triglycerides outside 135-500 mg/dL),
- non-matching background therapy (statin therapy not used),
- different dose (not about 4 g/day),
- different composition purity (omega-3 profile not meeting ≥96 wt.% threshold),
- duration not meeting the “at least about” thresholds.
However, the “about” and range-based drafting reduces categorical non-infringement.
What generic entry risks exist if a generic ethyl icosapentate launches in the US?
Legal mechanics depend on label and use. A generic can still be required to address method-of-use patents that are Orange Book-listed for specific indications.
Even if a generic is chemically identical, the method-of-use claim can become the primary risk if:
- the generic seeks the same clinical indication positioning,
- its label or submitted data effectively instructs the claimed regimen and patient selection,
- enforcement uses label carve-in or physician use theories consistent with the claimed method.
In practice: the highest infringement risk occurs where the generic’s label is aligned with:
- statin-treated population,
- fasting triglycerides in the claimed range,
- high-dose 4 g/day regimen,
- and endpoints consistent with revascularization/unstable angina.
How does US Patent 10,278,935 compare with other ethyl icosapentate patent types (composition vs method)?
Method-of-use (this patent)
- Controls clinical adoption and indication-specific uses.
- Can restrict competition even if drug substance is available.
Composition/formulation patents (typical adjacent families)
- Control manufacturing and capsule composition.
- Harder to design around without a different formulation route.
Process/manufacturing patents (typical adjacent families)
- Control how the drug is made.
- Risk is usually for manufacturing sites, supply chain, and contract manufacturing.
Business takeaway: method-of-use claims like 10,278,935 often become the last barrier to full indication-level entry, even when earlier formulation/substance layers fall away.
Key Takeaways
- US Patent 10,278,935 is a method-of-treatment IP layer covering ~4 g/day ethyl icosapentate administered for at least 2 years in statin-treated subjects (Claim 1) and for at least 4 months in subjects with established cardiovascular disease (Claim 19).
- The claims focus on fasting triglycerides ~135-500 mg/dL and include measurable lipid band sub-limitations and a baseline lipid measurement procedural step.
- Composition scope is anchored by omega-3 fatty acid purity ≥96 wt.% and dose delivery flexibility (1 to 4 units/day).
- Endpoint coverage extends beyond the core revascularization/unstable angina outcomes to MI, stroke, and cardiovascular death, allowing enforcement under multiple endpoint theories.
- Design-around options are concentrated in the hardest claim elements: dose (~4 g/day), purity (≥96 wt.%), patient eligibility (triglyceride range), and background therapy (statin requirement).
FAQs
- What clinical trial inclusion criteria best match US 10,278,935’s fasting triglyceride range and lipid bands?
- Can a competitor avoid infringement by using less than 4 g/day ethyl icosapentate or a different daily unit count?
- How do the washout exclusions on niacin/fibrates and omega-3 supplements affect real-world infringement risk?
- If a product is chemically identical, what label language most directly increases method-of-use infringement exposure under this patent?
- Which claim element (dose, purity, triglycerides, duration, or outcome) is typically the easiest to dispute during claim-chart litigation?
References (APA)
- United States Patent 10,278,935. (n.d.).
